Human myeloma cell lines (KMS12-BM, KMS12-PE, NCI-H929) and AML cell line MOLM13 were treated with the FLT3 inhibitors midostaurin and gilteritinib, an AKTserine/threonine inhibitor (API-2) in increasing concentrations ranging from 10 to 1000 nM, and the standard MM proteasome-inhibitor (bortezomib, 5–20 nM). The gene discussed is FLT3; the disease is Miyoshi myopathy.